tiprankstipranks
Trending News
More News >

BioCryst Sells BioCryst Ireland to Neopharmed Gentili

Story Highlights
BioCryst Sells BioCryst Ireland to Neopharmed Gentili

Don’t Miss TipRanks’ Half-Year Sale

The latest update is out from BioCryst ( (BCRX) ).

On June 27, 2025, BioCryst Pharmaceuticals entered into a Stock Purchase Agreement to sell its equity interests in BioCryst Ireland to Neopharmed Gentili S.p.A. for $250 million, with potential additional payments based on revenue milestones. This transaction, expected to close in October 2025, will involve amendments to existing intellectual property agreements and establish BioCryst as the exclusive supplier of ORLADEYO® to the company, impacting BioCryst’s operations and market positioning in Europe.

The most recent analyst rating on (BCRX) stock is a Buy with a $11.00 price target. To see the full list of analyst forecasts on BioCryst stock, see the BCRX Stock Forecast page.

Spark’s Take on BCRX Stock

According to Spark, TipRanks’ AI Analyst, BCRX is a Neutral.

BioCryst’s stock reflects a mixed outlook. Positive earnings call sentiment and strategic corporate events contribute to a favorable outlook, but financial instability and negative technical indicators pose significant risks. Future growth depends on continued revenue expansion and financial management.

To see Spark’s full report on BCRX stock, click here.

More about BioCryst

BioCryst Pharmaceuticals, Inc. is a pharmaceutical company involved in the development and commercialization of novel oral and small-molecule medicines. The company focuses on rare diseases, with ORLADEYO® being one of its primary products, particularly in the European market.

Average Trading Volume: 4,634,481

Technical Sentiment Signal: Buy

Current Market Cap: $1.96B

For a thorough assessment of BCRX stock, go to TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1